Literature DB >> 15126525

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Christina Wang1, Glenn Cunningham, Adrian Dobs, Ali Iranmanesh, Alvin M Matsumoto, Peter J Snyder, Thomas Weber, Nancy Berman, Laura Hull, Ronald S Swerdloff.   

Abstract

Transdermal testosterone (T) delivery represents an effective alternative to injectable androgens. We studied 163 hypogonadal men who applied 5, 7.5, or 10 g AndroGel (T gel) 1% CIII per day for up to 42 months. Efficacy data were presented in 123 subjects considered evaluable. Continuous AndroGel treatment normalized mean serum T and free T levels. Mean serum 5alpha-dihydrotestosterone concentrations and 5alpha-dihydrotestosterone/T ratio slightly increased, mean serum estradiol/T ratio doubled, and mean serum FSH and LH levels were suppressed by T replacement. Sexual function and mood parameters improved rapidly and were maintained throughout T treatment. Lean body mass increased (P = 0.0001) and fat mass decreased (P = 0.0001), and these changes were maintained with treatment but were not accompanied by significant increases in muscle strength. Increases in serum bone markers suggestive of increased bone formation were followed by gradual and progressive increases in bone mineral density more in the spine (P = 0.0001) than the hip (P = 0.0004). Mild local skin irritation occurred in 12 subjects, resulting in discontinuation in only one subject. Except for the anticipated increase in hematocrit and hemoglobin, there were no clinically significant changes in blood counts or biochemistry. In three subjects with elevated serum prostate-specific antigen, prostate biopsies showed cancer. We conclude that continued application of AndroGel resulted in beneficial effects similar to those with injectables and other transdermal preparations. This study was neither placebo controlled nor powered to determine the effects of T treatment on prostate cancer risk. Thus, monitoring for prostatic disease and assessment for erythrocytosis are strongly advised to reduce the risk of adverse events with T treatment of hypogonadal men.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126525     DOI: 10.1210/jc.2003-032006

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  139 in total

Review 1.  Body composition changes with testosterone replacement therapy following spinal cord injury and aging: A mini review.

Authors:  Tom E Nightingale; Pamela Moore; Joshua Harman; Refka Khalil; Ranjodh S Gill; Teodoro Castillo; Robert A Adler; Ashraf S Gorgey
Journal:  J Spinal Cord Med       Date:  2017-08-03       Impact factor: 1.985

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

3.  Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone.

Authors:  A Bojesen; N Birkebæk; K Kristensen; L Heickendorff; L Mosekilde; J S Christiansen; C H Gravholt
Journal:  Osteoporos Int       Date:  2010-07-24       Impact factor: 4.507

4.  Radionuclide decorporation: matching the biokinetics of actinides by transdermal delivery of pro-chelators.

Authors:  Yong Zhang; Matthew P Sadgrove; Russell J Mumper; Michael Jay
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

Review 5.  Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.

Authors:  Zachary J Solomon; Jorge Rivera Mirabal; Daniel J Mazur; Taylor P Kohn; Larry I Lipshultz; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2018-11-30

Review 6.  Andropause: is the emperor wearing any clothes?

Authors:  S H Tariq; M T Haren; M J Kim; J E Morley
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

Review 7.  [Is there a pharmacotherapy for libido disturbances in men?].

Authors:  F-M Köhn
Journal:  Urologe A       Date:  2006-08       Impact factor: 0.639

8.  Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study.

Authors:  Daniel F Kelly; Charlene Chaloner; Diana Evans; Amy Mathews; Pejman Cohan; Christina Wang; Ronald Swerdloff; Myung-Shin Sim; Jihey Lee; Mathew J Wright; Claudia Kernan; Garni Barkhoudarian; Kevin C J Yuen; Kevin Guskiewicz
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

9.  The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial.

Authors:  M Spitzer; S Basaria; T G Travison; M N Davda; L DeRogatis; S Bhasin
Journal:  Andrology       Date:  2013-03-15       Impact factor: 3.842

10.  Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.

Authors:  T Minnemann; M Schubert; S Freude; D Hübler; I Gouni-Berthold; C Schumann; A Christoph; M Oettel; M Ernst; U Mellinger; W Krone; F Jockenhövel
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.